Impairing Eukaryotic Elongation Factor 2 Kinase Activity Decreases Atherosclerotic Plaque Formation

Peng Zhang, Maziar Riazy, Matthew Gold, Shu Huei Tsai, Kelly McNagny, Christopher Proud, Vincent Duronio

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

We tested whether loss of eukaryotic elongation factor 2 kinase (eEF2K) activity in macrophages suppresses development of atherosclerosis by transplanting bone marrow from mice with mutant eEF2K into ldlr-/- mice. Sixteen weeks after high-fat diet feeding, mutant eEF2K hematopoietic chimeras had a dramatically reduced level of atherosclerotic plaque formation. M1-skewed macrophages from eEF2K knock-in mice have less tumour necrosis factor-α release and a lesser ability to induce expression of endothelial cell markers, providing a potential explanation for the role of eEF2K. Because eEF2K activity in cells of the hematopoietic compartment contributes to atherosclerosis development, drugs inhibiting eEF2K might have a beneficial effect in treatment of atherosclerosis.

Original languageEnglish
Pages (from-to)1684-1688
Number of pages5
JournalCanadian Journal of Cardiology
Volume30
Issue number12
DOIs
Publication statusPublished or Issued - 1 Dec 2014
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this